Telix Pharmaceuticals Ltd (ASX: TLX) shares jumped another 5% to $16.44 in Thursday afternoon trading, taking the ASX healthcare stock close to double its value since early February.

After such a stunning run, the obvious question is: where do brokers see Telix shares going over the next 12 months?

A powerful moat

Telix operates in one of the most specialised corners of healthcare: radiopharmaceuticals. These products combine radioactive isotopes with targeted therapies and diagnostics, helping doctors detect and treat diseases such as cancer with greater precision.

Importantly, this isn’t an industry where newcomers can simply walk in and compete overnight. Telix has built specialised capabilities, commercial infrastructure and a growing portfolio of products.

Turning a corner

Telix shares really turned a corner in February following a series of positive announcements from the company.

In August, Telix reported a 22% year-on-year increase in revenue to US$477 million, tracking towards the upper end of its FY26 guidance. Gross margin improved to 55%, while its Precision Medicine segment delivered an impressive 65% margin.

Adjusted EBITDA jumped 146% to US$52 million, while profit after tax reached US$38 million. That included a US$40 million payment from Regeneron.

Telix also reaffirmed its FY26 revenue and other income guidance of more than US$1 billion, with research and development expenditure expected to be between US$230 million and US$270 million.

That’s a powerful combination for Telix shares: revenue growth, expanding margins and improving profitability.

Can Telix shares keep climbing?

According to TradingView data, the analyst community remains remarkably bullish.

Fourteen of 17 analysts rate Telix shares a buy or strong buy, while the remaining three have a hold rating. The average price target sits at $25.05, implying potential upside of roughly 53% from $16.44 at the time of writing.

But there is a dissenting voice worth considering.

Bell Potter was pleased with Telix’s first-half performance but warned that competition could weigh on revenue later in the year. The broker now believes Telix shares are approaching fair value.

As a result, Bell Potter downgraded the stock from buy to hold while retaining its $19 price target.

That target still represents potential upside of roughly 16% from $16.44. However, the downgrade raises an important question after Telix’s extraordinary gains: how much of the good news is already priced in?

Foolish takeaway?

For investors, the bull case remains compelling. Telix is growing rapidly in a specialised market, profitability is improving, and most brokers still see substantial upside. But after a 98% surge, expectations are inevitably higher.

Telix shares may have plenty more room to run, but investors are no longer buying an undiscovered biotech. They’re buying a rapidly growing healthcare company with a much higher valuation and much higher expectations.

The post Telix shares are up 98%: Is there more upside to come? appeared first on The Motley Fool Australia.

More reading

• Telix shares are tumbling. Is the stock finally at fair value?
• Why were Telix shares just downgraded?
• 5 things to watch on the ASX 200 on Friday
• 7 ASX 200 shares with reaffirmed buy ratings this week
• Telix Pharmaceuticals delivers robust half-year earnings and pipeline progress

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares are up 0.55% at 9,027.8 points on Thursday.

Following the August reporting season, brokers have reviewed their ratings and 12-month price targets on hundreds of ASX stocks.

Here are some companies that scored reaffirmed buy ratings following their latest financial reports.

CSL Ltd (ASX: CSL)

The CSL share price is $175.12, up 0.7% today.

Over the past month, this ASX 200 healthcare share has ripped 41% higher.

Morgans renewed its buy rating on CSL shares with a 12-month price target of $187.71.

This suggests a potential 7% upside ahead.

Mineral Resources Ltd (ASX: MIN)

The Mineral Resources share price is $63.69, up 2.5% today.

This ASX 200 mining share has ascended 10% over the past month.

RBC Capital reiterated its buy rating on Mineral Resources shares with a price target of $80.

This implies a potential 25% upside ahead.

Santos Ltd (ASX: STO)

The Santos share price is $8.26, up 7.4% today.

This ASX 200 energy share has increased 8% over the past month.

Citi renewed its buy rating on Santos shares.

The broker raised its 12-month price target from $8.30 to $9.

This suggests a potential 9% upside ahead.

BHP Group Ltd (ASX: BHP)

The BHP share price is $64.01, down 1% today after going ex-dividend.

Over the past month, this ASX 200 copper share has risen 5%.

Morgan Stanley reaffirmed its buy rating on BHP shares.

The broker raised its 12-month target from $67.50 to $68.

This suggests a potential 6% upside ahead.

Lynas Rare Earths Ltd (ASX: LYC)

The Lynas share price is $15.46, up 2.3% today.

This ASX 200 mining share has leapt 10% over the past month.

JP Morgan reiterated its buy rating on Lynas shares with a price target of $19.10.

This implies a potential 23% upside ahead.

Nine Entertainment Co. Holdings Ltd (ASX: NEC)

The Nine Entertainment share price is 97 cents, up 1% today.

Over the past month, this ASX 200 communications share has fallen 2%.

Morgan Stanley reaffirmed its buy rating on Nine shares with a 12-month target of $1.40.

This suggests a potential 42% upside ahead.

Coles Group Ltd (ASX: COL)

The Coles share price is $23.58, up 0.3% today.

Over the past month, this ASX 200 consumer staples share has fallen 3%.

Morgan Stanley reiterated its buy rating on Coles shares.

The broker increased its price target from $25 to $25.80.

This implies potential capital gains of 9% ahead.

Qantas Airways Ltd (ASX: QAN)

The Qantas share price is $9.35, up 1.3% today.

This ASX 200 travel share has fallen 9% over the past month.

Morgan Stanley renewed its buy rating on Qantas shares with a $12.80 target.

This implies potential capital growth of 36% over the next year.

NextDC Ltd (ASX: NXT)

The NextDC share price is $12.70, down 0.2% today.

Over the past month, this ASX 200 tech share has fallen 6%.

UBS renewed its buy rating on NextDC shares with a $23.45 target.

This suggests a potential 85% upside ahead.

Paladin Energy Ltd (ASX: PDN)

The Paladin Energy share price is $11.31, up 1.8% today.

Over the past month, this ASX 200 uranium share has soared 20%.

Canaccord Genuity renewed its buy rating on Paladin Energy shares.

The broker raised its 12-month price target from $15.40 to $15.80.

This suggests a potential 40% upside ahead.

Flight Centre Travel Group Ltd (ASX: FLT)

The Flight Centre share price is $11.52, down 0.3% today.

Over the past month, this ASX 200 travel share has fallen 13%.

JP Morgan renewed its buy rating on Flight Centre shares with a $15.30 target.

This suggests a potential 32% upside ahead.

The post 11 ASX 200 shares with reaffirmed buy ratings post-results appeared first on The Motley Fool Australia.

More reading

• How CSL shares skyrocketed 39% in August
• Top 3 ASX 200 shares that lifted their dividend this reporting season
• Own BHP, Woodside or Coles shares? Here’s what investors should know
• Buying Santos shares? Here’s why the company is celebrating this production milestone
• How to invest in quantum computing on the ASX

Citigroup is an advertising partner of Motley Fool Money. JPMorgan Chase is an advertising partner of Motley Fool Money. Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and JPMorgan Chase. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Lynas Rare Earths Ltd. The Motley Fool Australia has recommended BHP Group, CSL, Flight Centre Travel Group, and Nine Entertainment. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

August was a great month for CSL Ltd (ASX: CSL) shares.

Not to mention the company’s shareholders.

In the month just past, the S&P/ASX 200 Index (ASX: XJO) gained a respectable 1.1%.

But the Aussie biotech giant left those gains in the dust.

Indeed, on 31 July, you could have bought CSL shares at market close for $123.06. When the closing bell sounded on 31 August, those shares were swapping hands for $171.57 apiece.

This put the ASX 200 biotech stock up a whopping 39.4% in August.

And this isn’t some microcap stock we’re talking about here. CSL commands a market cap of nearly $84 billion.

What sent CSL shares soaring in August?

At the beginning of August, the CSL share price was down more than 53% over the previous 12 months.

With investors seemingly sensing that the company’s ‘reset’ process is gaining traction, bargain hunters sent shares in the ASX 200 biotech up 9.4% by market close on 17 August.

Then, on 18 August, CSL announced its FY 2026 results.

Now, full year revenue of US$15.8 billion was down 1% from FY 2025. However, that significantly beat the company’s revised guidance (issued in May) of US$15.2 billion.

And CSL also operated at a loss, with reported net profit after tax (NPAT) coming in at a loss of US$2.6 billion.

Still, management declared an unfranked final dividend of $2.277 a share, down 7% from last year’s final dividend in Aussie dollar terms.

That passive income payout is still up for grabs, by the way. If you want to bank the final CSL dividend, you’ll need to own shares at market close on 8 September. You can then expect to get paid on 2 October.

So, why did CSL shares surge 17.3% on the day of the results release?

That looks to have been driven by expectations of a stronger year (and years) ahead.

“FY26 has been a year of reset. We have taken decisive action and created a clear path to return to sustainable growth,” CSL interim CEO Gordon Naylor said.

The ASX 200 biotech stock forecasts steady revenue in FY 2027, while it expects underlying NPAT to grow by around 5%.

Is it too late to buy the ASX 200 biotech stock today?

Despite the big surge in CSL shares in recent months, Morgans’ Damien Nguyen believes the ASX 200 biotech stock remains an appealing investment (courtesy of The Bull).

According to Nguyen, who issued a buy recommendation on CSL:

CSL is a global healthcare leader with strong competitive advantages across plasma therapies, vaccines and specialty medicines. Demand for its products remain largely independent of economic conditions.

Nguyen added:

In our view, the latest full year result in 2026 is generating confidence that repeated earnings downgrades are behind CSL.

With defensive earnings, global market leadership and attractive long term growth prospects, we view CSL as an appealing investment opportunity.

The post How CSL shares skyrocketed 39% in August appeared first on The Motley Fool Australia.

More reading

• 11 ASX 200 shares with reaffirmed buy ratings post-results
• CSL shares rebound 86%: Is the ASX biotech stock a buy, sell or hold for September?
• The 5 best ASX 200 stocks to buy and hold in August revealed
• Top 3 ASX shares to buy in September 2026
• CSL shares are up more than 40% in a month. What just happened in the US?

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.